GRI Bio, Inc. (GRI) Stock Score, Valuation & Financial Research

GRI Bio, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for GRI

GRI Bio, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.93. These figures are a research snapshot, not a buy or sell recommendation.

What GRI Bio, Inc. does

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

GRI Bio is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. It funds its operations primarily through the issuance of equity and debt securities to support the research and development of its proprietary pipeline of immune cell modulators.

Products and services

  • The company is developing a pipeline of therapies targeting inflammatory, fibrotic, and autoimmune diseases, including its lead candidate GRI-0621 and preclinical candidates GRI-0803, GRI-0124, and GRI-0729.

Customer types

Healthcare providers and patients (potential future market).

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on third-party contract research organizations to conduct its preclinical and clinical studies; specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Biopharmaceutical companies — The company competes with various established pharmaceutical and biotechnology companies that are developing therapies for inflammatory, fibrotic, and autoimmune diseases. Source

Business strengths to evaluate

  • Proprietary library of over 500 compounds Source
  • Focus on novel NKT cell modulation Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Need for additional capital to fund operations and clinical trials Source
  • Dependence on third-party clinical trial providers Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

GRI financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.93
Market capitalization:
4.22M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -9.66M
Free cash flow:
USD -10.19M
Cash:
USD 10.95M
Total debt:
USD 44K
EPS:
USD -43.70

What stands out

  • Free cash flow is USD -10.19M, negative for the stored period.
  • The balance sheet shows USD 10.95M of cash versus USD 44K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 10.9M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for GRI

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can GRI fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is GRI likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for GRI to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of GRI's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research GRI

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.